Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients
A legfontosabb adatok
- Hol
- Baltimore, La Jolla, Loma Linda, Madison, New York, Pittsburgh, Richmond és Salt Lake City (Egyesült Államok)Mind a 9 helyszín megnézése
Helyszínek itt: Egyesült Államok
- Johns Hopkins UniversityBaltimore, Egyesült ÁllamokContact: Christine Durand, MDRésztvevőt keres
- University of California San DiegoLa Jolla, Egyesült ÁllamokContact: Saima Aslam, MDRésztvevőt keres
- Loma Linda University HealthLoma Linda, Egyesült ÁllamokContact: Mina Rakoski, MDRésztvevőt keres
- University of Wisconsin - MadisonMadison, Egyesült ÁllamokContact: Christine Durand, MDNo longer taking part
- Icahn School of Medicine at Mount SinaiNew York, Egyesült ÁllamokContact: Susan Lerner, MDRésztvevőt keres
- NYU Langone HealthNew York, Egyesült ÁllamokContact: Aprajita Mattoo, MDRésztvevőt keres
- University of Pittsburgh Medical CenterPittsburgh, Egyesült ÁllamokContact: Fernanda Silveira, MDRésztvevőt keres
- Virginia Commonwealth UniversityRichmond, Egyesült ÁllamokContact: Gaurav Gupta, MDRésztvevőt keres
- University of Utah Medical CenterSalt Lake City, Egyesült ÁllamokContact: Christine Durand, MDNo longer taking part
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Johns Hopkins University
- Azonosító
- NCT05653232
- A regiszteradat frissítve
- 2026. szeptember 4.
- Eredeti leírás
This study is being done to find out the best time to start medication for Hepatitis C Virus (HCV) in HCV-negative recipients of HCV-positive (HCV D+/R-) kidney transplants. Participants will be randomized into one of two groups:A teljes eredeti leírásKevesebb
Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: a Randomized Controlled Trial
This study is being done to find out the best time to start medication for Hepatitis C Virus (HCV) in HCV-negative recipients of HCV-positive (HCV D+/R-) kidney transplants. Participants will be randomized into one of two groups:
Arm 1 - Prophylaxis: This group will start the HCV medication before transplant and will take a shorter course of HCV medication for 2 weeks.
Arm 2 - Transmit and Treat: This group will start the HCV medication after transplant and will take the full course (12 weeks) of HCV medication.
Bevonási feltételek: Participant meets the standard criteria for KT at local center; Participant is able to understand and provide informed consent; Participant is ≥ 18 years old.
Kizáró feltételek: Participant is unable to safely substitute or discontinue a medication that is contraindicated with the study medication; Participant has active HCV infection (detectable HCV RNA) at time of screening; Participant has human immunodeficiency virus infection (HIV), or active hepatitis B (HBV) infection; Participant's aspartate aminotransferase (AST) or ALT > 2.5 times the upper limit of normal (ULN), within 60 days of screen; Participant has cirrhosis or advanced liver fibrosis; Past or current medical problems, which may pose additional risks from participation in the study, interfere with the participant's ability to comply with study, or impact the quality of the data obtained from the study; Participant is pregnant or breastfeeding.